Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Sarcoma 2Mesothelioma 2Lung Neoplasms 2Esophageal Neoplasms 2Thymus Neoplasms 1Sarcoma, Ewing 1Neoplasms, Germ Cell and Embryonal 1Kidney Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

aldesleukin 24Cyclophosphamide 14Interferon-alpha 10fludarabine 8fludarabine phosphate 7Interleukin-2 6Chemotherapy, Adjuvant 6sargramostim 5Neoadjuvant Therapy 5Fluorouracil 4Vincristine 3Sunitinib 3Magnetic Resonance Spectroscopy 3Dactinomycin 3Carboplatin 3Bevacizumab 3Amplified Fragment Length Polymorphism Analysis 3vandetanib 2valspodar 2tanespimycin 2ixabepilone 2carboxyamido-triazole 2bryostatin 1 2Vinblastine 2Thalidomide 2Temozolomide 2Sorafenib 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Muromonab-CD3 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Kidney Neoplasms × Plicamycin × Clear all
NCT02859415 2022-04-05

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 10 charts
GastrointestinalGenitourinaryOther solid neoplasmSarcomaThoracic

Esophageal Neoplasms, Kidney Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasms, Germ Cell and Embryonal, Sarcoma, Thymus Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡